152 related articles for article (PubMed ID: 15663996)
1. Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.
Pelger RC; Lycklama A Nijeholt GA; Papapoulos SE; Hamdy NA
Bone; 2005 Jan; 36(1):1-5. PubMed ID: 15663996
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
[TBL] [Abstract][Full Text] [Related]
3. [Dense bone metastases and hypophosphatemic osteomalacia during the course of prostatic cancer (author's transl)].
Quilichini R; Aubert L; Chauvin M; Chaffanjon P; Eisinger J
Sem Hop; 1979 Dec 18-25; 55(43-44):2037-9. PubMed ID: 233449
[TBL] [Abstract][Full Text] [Related]
4. Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma.
Wei WJ; Sun ZK; Shen CT; Qiu ZL; Luo QY
Clin Nucl Med; 2017 Sep; 42(9):e405-e406. PubMed ID: 28719445
[TBL] [Abstract][Full Text] [Related]
5. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U
Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552
[TBL] [Abstract][Full Text] [Related]
6. Hypophosphatemic vitamin-D resistant rickets associated with epidermal nevus syndrome. A case report.
Tokatli A; Coşkun T; Ozalp I
Turk J Pediatr; 1997; 39(2):247-51. PubMed ID: 9223923
[TBL] [Abstract][Full Text] [Related]
7. Osteomalacia with hypophosphatemia and hypercalciuria: a possible new variant of osteomalacia.
Slyper AH; Shaker JL; Thometz JG; McCormick K
J Pediatr; 1995 Jul; 127(1):105-9. PubMed ID: 7608793
[TBL] [Abstract][Full Text] [Related]
8. Bone directed therapies for prostate cancer.
Bradley DA; Hussain M; Dipaola RS; Kantoff P
J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
Saad F; Sternberg CN
Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
[TBL] [Abstract][Full Text] [Related]
10. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
11. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
12. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
13. [Progressive course of hypophosphatemic osteomalacia during 25-year follow up].
Bojović J; Pavlica L
Med Pregl; 2010; 63(5-6):419-22. PubMed ID: 21186558
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approach to hormone-refractory prostate cancer.
Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
16. Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy.
Ramon I; Kleynen P; Valsamis J; Body JJ; Karmali R
Calcif Tissue Int; 2011 Dec; 89(6):442-5. PubMed ID: 21910004
[TBL] [Abstract][Full Text] [Related]
17. Challenging problems in advanced malignancy: Case 2. Disseminated intravascular coagulation in metastatic hormone-refractory prostate cancer.
Kampel LJ
J Clin Oncol; 2003 Aug; 21(16):3170-1. PubMed ID: 12915609
[No Abstract] [Full Text] [Related]
18. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
19. Bone scintigraphic findings of hypophosphatemic osteomalacia associated with adefovir therapy: involvement of lower extremity skeletons.
Kim DH; Lee SW; Kweon YO; Lee J; Ahn BC
Clin Nucl Med; 2013 May; 38(5):378-80. PubMed ID: 23478852
[TBL] [Abstract][Full Text] [Related]
20. [Hypophosphatemic osteomalacia].
Bullmann C; Benker G; Rosien U; Delling G; Siggelkow H; Schulte HM
Med Klin (Munich); 2008 Sep; 103(9):671-5. PubMed ID: 18813890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
